hek293t cells expressing sars cov 2 receptor human ace2 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
hek293t cells expressing sars cov 2 receptor human ace2
Hek293t Cells Expressing Sars Cov 2 Receptor Human Ace2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 38021 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ace2+receptor/293T/pmc13207987-70-0-13
Average 99 stars, based on 38021 article reviews
Hek293t Cells Expressing Sars Cov 2 Receptor Human Ace2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 38021 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+ace2+receptor/293T/pmc13207987-70-0-13
Average 99 stars, based on 38021 article reviews
hek293t cells expressing sars cov 2 receptor human ace2 - by Bioz Stars,
2026-09
99/100 stars
Images
1) Product Images from "Immunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant"
Article Title: Immunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant
Journal: International Journal of Molecular Sciences
doi: 10.3390/ijms27104218
Figure Legend Snippet: Construction and characterization of the XEC-S mRNA vaccine. ( A ) The XEC-S mRNA was constructed to encode the ectodomain S (S1 and S2 subunits) protein of the Omicron-XEC subvariant of SARS-CoV-2 with the HexaPro sequence, and to contain an N-terminal tissue plasminogen activator (tPA signal peptide), a C-terminal foldon trimeric sequence and a His 6 tag. The synthesized mRNA carrying a 5′-untranslated region (5′-UTR) and a 3′-UTR was capped at the 5′-terminus and tailed with a poly(A) sequence at the 3′-terminus, then encapsulated with lipid nanoparticles (LNPs) to form XEC-S-mRNA LNPs. Measured stability of the LNP-formulated XEC-S-mRNA ( B ) and control LNPs ( C ) by a DynaPro NanoStar II Light Scattering Detector (DLS) instrument. The samples were stored at 4 °C, 25 °C, and 37 °C for 1 to 7 days, then the particle sizes (diameters) were measured by the DLS. Histograms showing particle sizes of the LNP-formulated XEC-S-mRNA ( D ) and control LNPs ( E ). ( F ) Assessment of the expression of the His-tagged protein encoded by XEC-S-mRNA using flow cytometry. HEK293T cells were incubated with XEC-S mRNA-LNPs or the control LNPs, then stained with the anti-His-FITC antibody prior to conducting fluorescence intensity analysis using a flow cytometer. The shaded region indicates control cells incubated with LNPs, and the magenta line refers to target cells incubated with LNP-formulated XEC-S-mRNA. MFI: median fluorescence intensity.
Techniques Used: Construct, Sequencing, Synthesized, Control, Expressing, Flow Cytometry, Incubation, Staining, Fluorescence
Figure Legend Snippet: Assessment of humoral immune responses induced by the XEC-S-mRNA vaccine. ( A ) Immunization and challenge schedules. BALB/c-hACE2 transgenic mice were intradermally (i.d.) immunized with LNP-formulated XEC-S-mRNA or control LNPs and boosted twice at 3-week intervals; collection of sera followed 10 days after the last dose for measurement of subsequent antibody responses. Nine weeks after the last dose, the immunized mice were then intranasally (i.n.) challenged with an Omicron-KP.3 subvariant of SARS-CoV-2 to assess the protective efficacy. Evaluation of the XEC-S-specific IgG ( B ), IgG1 ( C ), and IgG2a ( D ) antibody (Ab) titers in sera by ELISA. The data refers to the mean ± standard deviation of the mean (s.e.m) of five mice in each group. The dotted lines indicate the detection limit (1:30). The experiments were repeated once, with similar results obtained.
Techniques Used: Transgenic Assay, Control, Enzyme-linked Immunosorbent Assay, Standard Deviation
Figure Legend Snippet: Evaluation of the broad neutralizing antibody responses induced by the XEC-S-mRNA vaccine. Mouse sera collected 10 days after the third immunization were assessed for a neutralizing antibody (Ab) titer against pseudotyped Omicron-KP.2 ( A ), KP.3 ( B ), XEC ( C ), NB.1.8.1 ( D ), and XFG ( E ) using a pseudovirus neutralization assay. The same sera were assessed for a neutralizing Ab titer against the infection of live SARS-CoV-2 Omicron subvariants, including KP.2 ( F ) and KP.3 ( G ), using a cytopathic effect (CPE)-based neutralization assay. The NT 50 (i.e., 50% neutralizing Ab titer) is shown as the mean ± s.e.m of five mice in each group. The dotted lines indicate the detection limit (1:60 for the pseudovirus neutralizing Ab titer, and 1:30 for the live virus neutralizing Ab titer). The experiments were repeated once, with similar results obtained.
Techniques Used: Neutralization, Infection, Virus
Figure Legend Snippet: The LNP-formulated XEC-S-mRNA vaccine protected against a SARS-CoV-2 Omicron-KP.3 challenge. Nine weeks after the final immunization, the BALB/c-hACE2 transgenic mice were challenged (i.n.) with an Omicron-KP.3 subvariant of SARS-CoV-2, then viral titers in the lungs ( A ) and trachea ( B ) were measured by means of the plaque assay 5 days post-challenge. The data (plaque-forming unit: PFU/mL of viral titers) is shown as the mean ± s.e.m of five mice in each group. The dotted lines indicate the detection limit (3.3 PFU/mL). The unpaired Student’s t test was used to analyze statistical significance between the XEC-S-mRNA and control LNP groups. ** indicates p < 0.01. The experiments were repeated once, with similar results obtained.
Techniques Used: Transgenic Assay, Plaque Assay, Control
Figure Legend Snippet: XEC-S-mRNA-induced neutralizing antibodies play a key role in the protection against a SARS-CoV-2 Omicron-KP.3 challenge. ( A ) Immunization and serum transfer schedules. BALB/c mice were immunized (i.d.) with LNP-formulated XEC-S-mRNA or control LNPs and boosted at 3, 6, and 22 weeks. The pooled sera collected at 10, 17, and 28 days after the last dose were assessed for neutralizing antibody (Ab) titers against pseudotyped ( B ) and live ( C ) Omicron-KP.3 subvariants of SARS-CoV-2, then injected (i.p.) into naïve B6-hACE2 transgenic mice. 6 h post serum-transfer, the mice were challenged (i.n.) with Omicron-KP.3; five days post-challenge, the lungs ( D ) and trachea ( E ) were collected and assessed for viral titers using the plaque assay. The NT 50 indicates a 50% neutralizing Ab titer, and the viral titer is expressed as PFU/mL. The data is shown as the mean ± s.e.m of duplicate or quadruple wells (for the pooled sera) or of five mice in each group (for the viral titer). The dotted lines indicate the detection limit (1:60 for the pseudovirus neutralizing Ab titer, 1:30 for the live virus neutralizing Ab titer, and 3.3 PFU/mL for the viral titer). The unpaired Student’s t test was used to analyze the statistical significance between the XEC-S-mRNA and control LNP groups. * and **** indicate p < 0.05 and p < 0.0001, respectively. The experiments were repeated once, with similar results obtained.
Techniques Used: Control, Injection, Transgenic Assay, Plaque Assay, Virus
Related Articles
Stable Transfection:Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (purchased from ATCC, # CRL-11268) and A549 cells stably expressing the Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (designated as HEK-293T/17 from ATCC, # CRL-11268) and A549 cells stably expressing the Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (purchased from ATCC, # CRL-11268) and A549 cells stably expressing the Expressing:Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (purchased from ATCC, # CRL-11268) and A549 cells stably expressing the Article Title: Antiviral Activity of Oligonucleotides Targeting the SARS-CoV-2 Genomic RNA Stem-Loop Sequences within the 3′-End of the ORF1b Article Snippet: The cell lines used were Vero E6 (BS-CCLO87, ATCC, Rockville, MD, USA) cultivated using DMEM culture medium supplemented with 10% fetal bovine serum (FBS). .. In some experiments, human breast adenocarcinoma cells (MCF-7, HTB-22, ATCC) transiently expressing Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (designated as HEK-293T/17 from ATCC, # CRL-11268) and A549 cells stably expressing the Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (purchased from ATCC, # CRL-11268) and A549 cells stably expressing the Article Title: Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant. Article Snippet: Pseudoviruses expressing luciferase, including Prototype (GM-0220PV07), Delta (GM-0220PV45) and various Omicron sublineages: BA.2.75 (GM-0220PV99), BA.5 (GM-0220PV90), BF.7 (GM-0220PV100), BQ.1 (GM-0220PV103), BQ.1.1 (GM-0220PV105), XBB (GM-0220PV102), XBB.1.5 (GM-0220PV102), XBB.1.16 (GM-0220PV120), XBB.1.6 (GM-0220PV116), XBB.1.9.1 (GM-0220PV113) and XBB.2.3 (GM-0220PV115), were obtained from Genomeditech. .. In brief, the inactivated sera, BALF, NLF and nasal swab wash samples (56 °C for 30 min) were subjected to a 3-fold serial dilution, ranging from 30 to 65,610-fold, and then incubated with equal volumes of different diluted pseudoviruses at 37 °C for 1 h. Subsequently, 1.2 × 104 HEK293T cells (ATCC, CRL-11268) expressing Modification:Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (purchased from ATCC, # CRL-11268) and A549 cells stably expressing the Article Title: Antiviral Activity of Oligonucleotides Targeting the SARS-CoV-2 Genomic RNA Stem-Loop Sequences within the 3′-End of the ORF1b Article Snippet: The cell lines used were Vero E6 (BS-CCLO87, ATCC, Rockville, MD, USA) cultivated using DMEM culture medium supplemented with 10% fetal bovine serum (FBS). .. In some experiments, human breast adenocarcinoma cells (MCF-7, HTB-22, ATCC) transiently expressing Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (designated as HEK-293T/17 from ATCC, # CRL-11268) and A549 cells stably expressing the Article Title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors Article Snippet: .. HEK-293T cells (purchased from ATCC, # CRL-11268) and A549 cells stably expressing the Plasmid Preparation:Article Title: Antiviral Activity of Oligonucleotides Targeting the SARS-CoV-2 Genomic RNA Stem-Loop Sequences within the 3′-End of the ORF1b Article Snippet: The cell lines used were Vero E6 (BS-CCLO87, ATCC, Rockville, MD, USA) cultivated using DMEM culture medium supplemented with 10% fetal bovine serum (FBS). .. In some experiments, human breast adenocarcinoma cells (MCF-7, HTB-22, ATCC) transiently expressing Serial Dilution:Article Title: Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant. Article Snippet: Pseudoviruses expressing luciferase, including Prototype (GM-0220PV07), Delta (GM-0220PV45) and various Omicron sublineages: BA.2.75 (GM-0220PV99), BA.5 (GM-0220PV90), BF.7 (GM-0220PV100), BQ.1 (GM-0220PV103), BQ.1.1 (GM-0220PV105), XBB (GM-0220PV102), XBB.1.5 (GM-0220PV102), XBB.1.16 (GM-0220PV120), XBB.1.6 (GM-0220PV116), XBB.1.9.1 (GM-0220PV113) and XBB.2.3 (GM-0220PV115), were obtained from Genomeditech. .. In brief, the inactivated sera, BALF, NLF and nasal swab wash samples (56 °C for 30 min) were subjected to a 3-fold serial dilution, ranging from 30 to 65,610-fold, and then incubated with equal volumes of different diluted pseudoviruses at 37 °C for 1 h. Subsequently, 1.2 × 104 HEK293T cells (ATCC, CRL-11268) expressing Incubation:Article Title: Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant. Article Snippet: Pseudoviruses expressing luciferase, including Prototype (GM-0220PV07), Delta (GM-0220PV45) and various Omicron sublineages: BA.2.75 (GM-0220PV99), BA.5 (GM-0220PV90), BF.7 (GM-0220PV100), BQ.1 (GM-0220PV103), BQ.1.1 (GM-0220PV105), XBB (GM-0220PV102), XBB.1.5 (GM-0220PV102), XBB.1.16 (GM-0220PV120), XBB.1.6 (GM-0220PV116), XBB.1.9.1 (GM-0220PV113) and XBB.2.3 (GM-0220PV115), were obtained from Genomeditech. .. In brief, the inactivated sera, BALF, NLF and nasal swab wash samples (56 °C for 30 min) were subjected to a 3-fold serial dilution, ranging from 30 to 65,610-fold, and then incubated with equal volumes of different diluted pseudoviruses at 37 °C for 1 h. Subsequently, 1.2 × 104 HEK293T cells (ATCC, CRL-11268) expressing Luciferase:Article Title: Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant. Article Snippet: Pseudoviruses expressing luciferase, including Prototype (GM-0220PV07), Delta (GM-0220PV45) and various Omicron sublineages: BA.2.75 (GM-0220PV99), BA.5 (GM-0220PV90), BF.7 (GM-0220PV100), BQ.1 (GM-0220PV103), BQ.1.1 (GM-0220PV105), XBB (GM-0220PV102), XBB.1.5 (GM-0220PV102), XBB.1.16 (GM-0220PV120), XBB.1.6 (GM-0220PV116), XBB.1.9.1 (GM-0220PV113) and XBB.2.3 (GM-0220PV115), were obtained from Genomeditech. .. In brief, the inactivated sera, BALF, NLF and nasal swab wash samples (56 °C for 30 min) were subjected to a 3-fold serial dilution, ranging from 30 to 65,610-fold, and then incubated with equal volumes of different diluted pseudoviruses at 37 °C for 1 h. Subsequently, 1.2 × 104 HEK293T cells (ATCC, CRL-11268) expressing other:Article Title: An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2. Article Snippet: Strain or plasmid Genotype/resistance/description Reference E. coli DH5αλpir F−8801lacZ1M151(argF lac)U169 deoR recA1 endA1 hsdR17 (rK−mK+) supE44 thi-1 gyrA69 relA1, λpirR6K, Apr Hanahan, 1983 SM10λpir thi thr leu tonA lacY supE recA::RPA-2-Te::Mu λpirR6K, Kmr Miller and Mekalanos, 1988 E-WT H10407-S, wild type ETEC strain; serotype O78:H11; CFA/I LT+ STh+ STp+, Smr Evans and Evans, 1973 E1msbB1eltA H10407 1msbB1eltA; Smr Leitner et al., 2015 E111 H10407 1msbB1eltA1ompA, Smr This study V. cholerae V-WT AC53, wild type V. cholerae strain serogroup: O1; biotype: El Tor; serotype: Ogawa; spontaneous Smr mutant of E7946; clinical isolate from Bahrain 1978; hapR+, Smr; used for previous immunization studies (Schild et al., 2008, 2009; Bishop et al., 2010, 2012; Leitner et al., 2013) Miller et al., |
